Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)
Close on Nov 18, 2026Market cap $3.39BP/E –Yield –
Iovance Biotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Iovance Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$301.31M. For fiscal 2025 it was -$403.36M. The highest annual figure on record is -$15.77K in fiscal 2009.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$403.36M | – |
| FY2024 | Dec 31, 2024 | -$395.28M | – |
| FY2023 | Dec 31, 2023 | -$460.56M | – |
| FY2022 | Dec 31, 2022 | -$398.88M | – |
| FY2021 | Dec 31, 2021 | -$342.70M | – |
| FY2020 | Dec 31, 2020 | -$261.94M | – |
| FY2019 | Dec 31, 2019 | -$206.87M | – |
| FY2018 | Dec 31, 2018 | -$128.26M | – |
| FY2017 | Dec 31, 2017 | -$92.88M | – |
| FY2016 | Dec 31, 2016 | -$53.64M | – |
| FY2015 | Dec 31, 2015 | -$27.86M | – |
| FY2014 | Dec 31, 2014 | -$12.04M | – |
| FY2013 | Dec 31, 2013 | -$22.64M | – |
| FY2012 | Dec 31, 2012 | -$8.13M | – |
| FY2011 | Dec 31, 2011 | -$21.22M | – |
| FY2010 | Dec 31, 2010 | -$815.41K | – |
| FY2009 | Dec 31, 2009 | -$15.77K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$51.91M | – |
| Q1 FY2026 | Mar 31, 2026 | -$81.04M | – |
| Q4 FY2025 | Dec 31, 2025 | -$73.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$94.90M | – |
| Q2 FY2025 | Jun 30, 2025 | -$113.77M | – |
| Q1 FY2025 | Mar 31, 2025 | -$121.22M | – |
| Q4 FY2024 | Dec 31, 2024 | -$86.58M | – |
| Q3 FY2024 | Sep 30, 2024 | -$89.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$101.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$117.72M | – |
| Q4 FY2023 | Dec 31, 2023 | -$121.26M | – |
| Q3 FY2023 | Sep 30, 2023 | -$118.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$110.09M | – |
| Q1 FY2023 | Mar 31, 2023 | -$110.86M | – |
| Q4 FY2022 | Dec 31, 2022 | -$107.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$100.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$99.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$91.71M | – |
| Q4 FY2021 | Dec 31, 2021 | -$99.47M | – |
| Q3 FY2021 | Sep 30, 2021 | -$86.24M | – |
| Q2 FY2021 | Jun 30, 2021 | -$81.43M | – |
| Q1 FY2021 | Mar 31, 2021 | -$75.57M | – |
| Q4 FY2020 | Dec 31, 2020 | -$68.53M | – |
| Q3 FY2020 | Sep 30, 2020 | -$58.97M | – |
| Q2 FY2020 | Jun 30, 2020 | -$63.63M | – |
| Q1 FY2020 | Mar 31, 2020 | -$70.81M | – |
| Q4 FY2019 | Dec 31, 2019 | -$65.11M | – |
| Q3 FY2019 | Sep 30, 2019 | -$51.61M | – |
| Q2 FY2019 | Jun 30, 2019 | -$50.17M | – |
| Q1 FY2019 | Mar 31, 2019 | -$39.99M | – |
| Q4 FY2018 | Dec 31, 2018 | -$34.94M | – |
| Q3 FY2018 | Sep 30, 2018 | -$35.06M | – |
| Q2 FY2018 | Jun 30, 2018 | -$31.38M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.88M | – |
| Q4 FY2017 | Dec 31, 2017 | -$26.07M | – |
| Q3 FY2017 | Sep 30, 2017 | -$22.34M | – |
| Q2 FY2017 | Jun 30, 2017 | -$23.58M | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.88M | – |
| Q4 FY2016 | Dec 31, 2016 | -$15.92M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.98M | – |
See a number that looks wrong?